The effect of matrix bound parathyroid hormone on bone regeneration

Ronald E. Jung, David L Cochran, Olivier Domken, Reinhart Seibl, Archie A Jones, Daniel Buser, Christoph H F Hammerle

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Introduction: Autogenous bone is the most successful bone-grafting material; however, multiple disadvantages continue to drive developments of improved methods for bone regeneration. Aim: The aim of the present study was to test the hypothesis that an arginine-glycine-aspartic acid (RGD) modified polyethylene glycol-based matrix (PEG) containing covalently bound peptides of the parathyroid hormone (PTH1-34) enhances bone regeneration to a degree similar to autogenous bone. Material and methods: Six American foxhounds received a total of 48 cylindrical titanium implants placed in the mandible between the first premolar and the second molar. Five, respectively, 7 months following tooth extraction, implants were placed into the center of surgically created defects. This resulted in a circumferential bone defect simulating an alveolar defect with a circular gap of 1.5 mm. Four treatment modalities were randomly allocated to the four defects per side: (1) PEG-matrix containing 20 μg/ml of PTH1-34, and 350 μg/ml cys-RGD peptide, (2) PEG alone, (3) autogenous bone and (4) empty defects. Histomorphometric analysis was performed 4 and 12 weeks after implantation. The area fraction of newly formed bone was determined within the former defect and the degree of bone-to-implant contact (BIC) was evaluated both in the defect region and in the apical region of the implant. For statistical analysis ANOVA and subsequent pairwise Student's t-test were applied. Results: Healing was uneventful and all implants were histologically integrated. Histomorphometric analysis after 4 weeks showed an average area fraction of newly formed bone of 41.7±1.8% for matrix-PTH, 26.6±4.1% for PEG alone, 43.9±4.5% for autogenous bone, and 28.9±1.5% for empty defects. After 12 weeks, the respective values were 49.4±7.0% for matrix-PTH, 39.3±5.7% for PEG alone, 50.5±3.4% for autogenous bone and 38.7±1.9% for empty defects. Statistical analysis after 4 and 12 weeks revealed significantly more newly formed bone in the PTH1-34 group compared with PEG alone or empty defects, whereas no difference could be detected against autogenous bone. Regarding BIC no significant difference was observed between the four treatment groups neither at 4 nor at 12 weeks. Conclusion: It is concluded that an RGD-modified PEG hydrogel containing PTH1-34 is an effective matrix system to obtain bone regeneration.

Original languageEnglish (US)
Pages (from-to)319-325
Number of pages7
JournalClinical Oral Implants Research
Volume18
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Bone Regeneration
Parathyroid Hormone
Bone and Bones
Tooth Extraction
Bone Matrix
Bone Transplantation
Peptide Hormones
Hydrogel
Bicuspid
Titanium
Mandible
Aspartic Acid
Glycine
Arginine
Analysis of Variance
Students

Keywords

  • Bone regeneration
  • Carrier material
  • Dental implants
  • Parathyroid hormone
  • Polyethylene glycol

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

The effect of matrix bound parathyroid hormone on bone regeneration. / Jung, Ronald E.; Cochran, David L; Domken, Olivier; Seibl, Reinhart; Jones, Archie A; Buser, Daniel; Hammerle, Christoph H F.

In: Clinical Oral Implants Research, Vol. 18, No. 3, 06.2007, p. 319-325.

Research output: Contribution to journalArticle

Jung, Ronald E. ; Cochran, David L ; Domken, Olivier ; Seibl, Reinhart ; Jones, Archie A ; Buser, Daniel ; Hammerle, Christoph H F. / The effect of matrix bound parathyroid hormone on bone regeneration. In: Clinical Oral Implants Research. 2007 ; Vol. 18, No. 3. pp. 319-325.
@article{e2218d6140c941998a7a572775dc39e9,
title = "The effect of matrix bound parathyroid hormone on bone regeneration",
abstract = "Introduction: Autogenous bone is the most successful bone-grafting material; however, multiple disadvantages continue to drive developments of improved methods for bone regeneration. Aim: The aim of the present study was to test the hypothesis that an arginine-glycine-aspartic acid (RGD) modified polyethylene glycol-based matrix (PEG) containing covalently bound peptides of the parathyroid hormone (PTH1-34) enhances bone regeneration to a degree similar to autogenous bone. Material and methods: Six American foxhounds received a total of 48 cylindrical titanium implants placed in the mandible between the first premolar and the second molar. Five, respectively, 7 months following tooth extraction, implants were placed into the center of surgically created defects. This resulted in a circumferential bone defect simulating an alveolar defect with a circular gap of 1.5 mm. Four treatment modalities were randomly allocated to the four defects per side: (1) PEG-matrix containing 20 μg/ml of PTH1-34, and 350 μg/ml cys-RGD peptide, (2) PEG alone, (3) autogenous bone and (4) empty defects. Histomorphometric analysis was performed 4 and 12 weeks after implantation. The area fraction of newly formed bone was determined within the former defect and the degree of bone-to-implant contact (BIC) was evaluated both in the defect region and in the apical region of the implant. For statistical analysis ANOVA and subsequent pairwise Student's t-test were applied. Results: Healing was uneventful and all implants were histologically integrated. Histomorphometric analysis after 4 weeks showed an average area fraction of newly formed bone of 41.7±1.8{\%} for matrix-PTH, 26.6±4.1{\%} for PEG alone, 43.9±4.5{\%} for autogenous bone, and 28.9±1.5{\%} for empty defects. After 12 weeks, the respective values were 49.4±7.0{\%} for matrix-PTH, 39.3±5.7{\%} for PEG alone, 50.5±3.4{\%} for autogenous bone and 38.7±1.9{\%} for empty defects. Statistical analysis after 4 and 12 weeks revealed significantly more newly formed bone in the PTH1-34 group compared with PEG alone or empty defects, whereas no difference could be detected against autogenous bone. Regarding BIC no significant difference was observed between the four treatment groups neither at 4 nor at 12 weeks. Conclusion: It is concluded that an RGD-modified PEG hydrogel containing PTH1-34 is an effective matrix system to obtain bone regeneration.",
keywords = "Bone regeneration, Carrier material, Dental implants, Parathyroid hormone, Polyethylene glycol",
author = "Jung, {Ronald E.} and Cochran, {David L} and Olivier Domken and Reinhart Seibl and Jones, {Archie A} and Daniel Buser and Hammerle, {Christoph H F}",
year = "2007",
month = "6",
doi = "10.1111/j.1600-0501.2007.01342.x",
language = "English (US)",
volume = "18",
pages = "319--325",
journal = "Clinical Oral Implants Research",
issn = "0905-7161",
publisher = "Blackwell Munksgaard",
number = "3",

}

TY - JOUR

T1 - The effect of matrix bound parathyroid hormone on bone regeneration

AU - Jung, Ronald E.

AU - Cochran, David L

AU - Domken, Olivier

AU - Seibl, Reinhart

AU - Jones, Archie A

AU - Buser, Daniel

AU - Hammerle, Christoph H F

PY - 2007/6

Y1 - 2007/6

N2 - Introduction: Autogenous bone is the most successful bone-grafting material; however, multiple disadvantages continue to drive developments of improved methods for bone regeneration. Aim: The aim of the present study was to test the hypothesis that an arginine-glycine-aspartic acid (RGD) modified polyethylene glycol-based matrix (PEG) containing covalently bound peptides of the parathyroid hormone (PTH1-34) enhances bone regeneration to a degree similar to autogenous bone. Material and methods: Six American foxhounds received a total of 48 cylindrical titanium implants placed in the mandible between the first premolar and the second molar. Five, respectively, 7 months following tooth extraction, implants were placed into the center of surgically created defects. This resulted in a circumferential bone defect simulating an alveolar defect with a circular gap of 1.5 mm. Four treatment modalities were randomly allocated to the four defects per side: (1) PEG-matrix containing 20 μg/ml of PTH1-34, and 350 μg/ml cys-RGD peptide, (2) PEG alone, (3) autogenous bone and (4) empty defects. Histomorphometric analysis was performed 4 and 12 weeks after implantation. The area fraction of newly formed bone was determined within the former defect and the degree of bone-to-implant contact (BIC) was evaluated both in the defect region and in the apical region of the implant. For statistical analysis ANOVA and subsequent pairwise Student's t-test were applied. Results: Healing was uneventful and all implants were histologically integrated. Histomorphometric analysis after 4 weeks showed an average area fraction of newly formed bone of 41.7±1.8% for matrix-PTH, 26.6±4.1% for PEG alone, 43.9±4.5% for autogenous bone, and 28.9±1.5% for empty defects. After 12 weeks, the respective values were 49.4±7.0% for matrix-PTH, 39.3±5.7% for PEG alone, 50.5±3.4% for autogenous bone and 38.7±1.9% for empty defects. Statistical analysis after 4 and 12 weeks revealed significantly more newly formed bone in the PTH1-34 group compared with PEG alone or empty defects, whereas no difference could be detected against autogenous bone. Regarding BIC no significant difference was observed between the four treatment groups neither at 4 nor at 12 weeks. Conclusion: It is concluded that an RGD-modified PEG hydrogel containing PTH1-34 is an effective matrix system to obtain bone regeneration.

AB - Introduction: Autogenous bone is the most successful bone-grafting material; however, multiple disadvantages continue to drive developments of improved methods for bone regeneration. Aim: The aim of the present study was to test the hypothesis that an arginine-glycine-aspartic acid (RGD) modified polyethylene glycol-based matrix (PEG) containing covalently bound peptides of the parathyroid hormone (PTH1-34) enhances bone regeneration to a degree similar to autogenous bone. Material and methods: Six American foxhounds received a total of 48 cylindrical titanium implants placed in the mandible between the first premolar and the second molar. Five, respectively, 7 months following tooth extraction, implants were placed into the center of surgically created defects. This resulted in a circumferential bone defect simulating an alveolar defect with a circular gap of 1.5 mm. Four treatment modalities were randomly allocated to the four defects per side: (1) PEG-matrix containing 20 μg/ml of PTH1-34, and 350 μg/ml cys-RGD peptide, (2) PEG alone, (3) autogenous bone and (4) empty defects. Histomorphometric analysis was performed 4 and 12 weeks after implantation. The area fraction of newly formed bone was determined within the former defect and the degree of bone-to-implant contact (BIC) was evaluated both in the defect region and in the apical region of the implant. For statistical analysis ANOVA and subsequent pairwise Student's t-test were applied. Results: Healing was uneventful and all implants were histologically integrated. Histomorphometric analysis after 4 weeks showed an average area fraction of newly formed bone of 41.7±1.8% for matrix-PTH, 26.6±4.1% for PEG alone, 43.9±4.5% for autogenous bone, and 28.9±1.5% for empty defects. After 12 weeks, the respective values were 49.4±7.0% for matrix-PTH, 39.3±5.7% for PEG alone, 50.5±3.4% for autogenous bone and 38.7±1.9% for empty defects. Statistical analysis after 4 and 12 weeks revealed significantly more newly formed bone in the PTH1-34 group compared with PEG alone or empty defects, whereas no difference could be detected against autogenous bone. Regarding BIC no significant difference was observed between the four treatment groups neither at 4 nor at 12 weeks. Conclusion: It is concluded that an RGD-modified PEG hydrogel containing PTH1-34 is an effective matrix system to obtain bone regeneration.

KW - Bone regeneration

KW - Carrier material

KW - Dental implants

KW - Parathyroid hormone

KW - Polyethylene glycol

UR - http://www.scopus.com/inward/record.url?scp=34547230118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547230118&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0501.2007.01342.x

DO - 10.1111/j.1600-0501.2007.01342.x

M3 - Article

C2 - 17386063

AN - SCOPUS:34547230118

VL - 18

SP - 319

EP - 325

JO - Clinical Oral Implants Research

JF - Clinical Oral Implants Research

SN - 0905-7161

IS - 3

ER -